Posted inClinical Updates Rheumatology Targeting FcRn to Combat Systemic Sclerosis: Promising Preclinical Advances with Efgartigimod Posted by By MedXY 11/20/2026No Comments IntroductionStudy Background and Unmet Medical NeedStudy Design and MethodsSpecialty calculatorsBrowse calculatorsFor clinical reference; use professional judgment. MedXY View All Posts Post navigation Previous Post Reevaluating Mandatory Sobriety Periods: Impact on Liver Transplant Outcomes in Alcohol-Associated Liver DiseaseNext PostIntegrating Children into the Primary Care Investment Conversation: A Critical Imperative